South Korea's Coreline Soft enters Australian market for lung cancer screening

21 February 2025 | News

Strategic partnership with Australian comprehensive healthcare company ParagonCare

South Korea-based Coreline Soft, a global leader in artificial intelligence (AI)-based medical solutions, has announced its entry into Australia, one of the three major medical device markets in Asia and the Atlantic. It recently revealed a strategic partnership with ParagonCare, a leading Australian comprehensive healthcare company.

This partnership focuses on accelerating lung cancer screening projects at major hospitals based on the Australian National Lung Cancer Screening Programme, which will be launched in July, and improving the quality of healthcare services in Australia through experience in operating AI-based workflows.

The two companies plan to combine ParagonCare's extensive distribution network and Coreline Soft's technological innovation to set a new standard for the Australian healthcare system.

The AVIEW LCS Plus is a product that has already been used for national lung cancer screening in several European countries. It has a track record of improving diagnostic accuracy and operational efficiency by being optimized for large-scale diagnostic programs.

It has been supplied to national lung cancer screening projects such as Germany's HANSE, Italy's RISP, and 4ITRL, which involved five European countries, achieving significant success and accelerating the introduction of AI screening processes. Following the success of HANSE, AI has been recommended as a mandatory first-line diagnosis for lung cancer screening in Germany, with similar movements noted in major European countries including France.